A new study developed a mineralized DNA hydrogel that combines immune regulation with sustained bone regeneration. Using ...
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...
NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...
In a recent study posted to the bioRxiv* preprint server, researchers performed age-reversing experiments, in vivo and in vitro, in progeroid mice using gene therapy. Study: Gene Therapy Mediated ...
AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks For Beijing-based METiS TechBio CEO Lai Tsai-ta, ageing is ...
Researchers have attained the holy grail of cellular reprogramming: inducing pluripotency without using any DNA-based materials. Using only a cocktail of purified proteins and a chemical additive, ...
Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results